

Contents

Preface — V

Chapter 1

Introductory concepts: fundamentals of metal complexes – an overview — 1

- 1.1 Metal-ligand bond — 1
- 1.2 Bond types — 1
 - 1.2.1 σ bonds — 2
 - 1.2.2 π bonds — 2
 - 1.2.3 d–d π bonding — 2
 - 1.2.4 d–p π bond — 3
- 1.3 Coordination number — 3
- 1.4 Classification of metals — 4
 - 1.4.1 Class A and class B metals — 4
- 1.5 Metal-metal bond in coordination compounds — 5
- 1.6 Ligands — 5
- 1.7 Isomerism and chirality — 6
- 1.8 Structural isomers — 6
- 1.9 Geometric isomers — 8
- 1.10 Conclusion — 10
- 1.11 Chirality — 10
- 1.12 Medicinal inorganic chemistry and transition metal complexes — 11
 - 1.12.1 Anticancer drugs — 11
 - 1.12.2 Anti-inflammatory drugs — 11
 - 1.12.3 Antidiabetic drugs — 12
 - 1.12.4 Antimicrobials — 12
 - 1.12.5 Metal deficiency diseases — 12
 - 1.12.6 Biomineralization — 12
 - 1.12.7 Degenerative diseases per se metals — 12
- 1.13 Metals and related compounds in alternative systems of medicine — 13
 - 1.13.1 Ayurveda — 13
- 1.14 Quantum logic in Ayurveda — 14
- 1.15 Chinese alternative system of medicine or traditional Chinese medicinal methods (TCMM) — 15
- 1.16 Zuotai: Tibetan medicine — 16
 - 1.16.1 Treatment — 16
- 1.17 Metal chelates in biological systems — 17
- 1.18 Quantitative structure-activity relationship (QSAR) — 17
- 1.19 Sustainable medicine — 17
- 1.20 AI in drug discovery and development — 18

1.21	Computer-aided drug designing (CADD) —	18
1.22	Prediction of activity spectra of substance (PASS) —	19
1.23	Absorption, distributions, metabolism, excretion (ADME) and toxicity profiling —	19
1.24	Molecular docking —	20
1.25	Nanomedicine and metal-based nanomedicines —	20
	References —	21

Chapter 2

Metal-based therapies in alternative and traditional system — 23

2.1	Ayurveda —	23
2.1.1	Metal-based therapy in the system —	25
2.1.2	Bhasmas —	25
2.1.3	Svarna Bhasma (gold) —	26
2.1.4	Organoleptic characteristics of Svarna Bhasma and composition —	26
2.1.5	Therapeutic indications —	27
2.1.6	Testing of Bhasma —	27
2.1.7	Rajata (silver) Bhasma —	27
2.1.8	Copper (tamra) Bhasma —	28
2.1.9	Lauha Bhasma (iron) —	29
2.1.10	Lead (Naga) Bhasma —	30
2.1.11	Yashada Bhasma (Zinc Bhasma) —	30
2.2	Metals in traditional Chinese medicinal materials (TCMM): an overview —	31
2.3	Zuotai in Tibetan medicine —	32
2.3.1	Pharmacological studies on herbometallic preparations —	32
2.4	Hypothesis for explaining mechanism of beneficial effects of Bhasmas and Zuotai —	33
2.5	Possible adaptation mechanism for Bhasmas and Zuotai —	33
2.6	Conclusion —	34
	References —	36

Chapter 3

Theoretical drug designing and sustainable medicine: a new paradigm — 39

3.1	Sustainable medicine: the future of healthcare —	39
3.2	Sustainability in drug discovery —	39
3.3	Artificial intelligence in drug discovery and development —	40
3.4	Future challenges of AI —	41
3.5	Theoretical drug designing —	41
3.6	Computer-aided drug design (CADD) —	42
3.7	Available tools for theoretical drug design —	43
3.7.1	Prediction of activity spectra of substance (PASS) —	43

- 3.7.2 The absorption, distribution, metabolism, excretion (ADME) and toxicity profiling — **44**
- 3.7.3 Molecular docking: a powerful tool for structure-based drug discovery — **45**
- 3.7.4 Swiss ADME: a smart method for small molecules — **48**
- 3.8 Summary — **49**
- References — **49**

Chapter 4

Metal complexes and their therapeutic applications — 51

- 4.1 Mechanism of action of metal complexes — **51**
- 4.2 DNA binding with metal complexes: a brief account — **52**
 - 4.2.1 Intercalation — **52**
 - 4.2.2 Outer sphere binding — **53**
 - 4.2.3 Inner sphere (covalent) binding — **53**
 - 4.2.4 Strand breakage — **53**
- 4.3 Transition metal complexes of bioactive ligands: application for drug delivery — **54**
 - 4.3.1 What are chaperones? — **54**
 - 4.3.2 What is the role of chaperones? — **54**
- 4.4 Classification of metal-based drugs — **55**
 - 4.4.1 Covalent binding of metal-based drugs to biomolecules — **56**
 - 4.4.2 Inhibition of enzymes — **57**
 - 4.4.3 Redox-active drugs — **57**
 - 4.4.4 Photodynamic and photoactivated chemotherapy — **58**
 - 4.4.5 Metal complexes for delivery and release of pharmacologically active ligands — **59**
 - 4.4.6 Catalytic drugs — **60**
 - 4.4.7 Radioactive agents for therapeutic application — **61**
 - 4.4.8 General mechanism of drug action — **61**
 - 4.4.9 Anticancer drugs — **62**
 - 4.4.10 Metal complexes of other metals for therapeutic applications — **64**
 - 4.4.11 Gold antiarthritic drugs — **64**
 - 4.4.12 Antitumor activity of metal complexes — **64**
 - 4.4.13 Therapeutic application of metal-based as antimicrobial agents — **65**
 - 4.4.14 Miscellaneous complexes and application as drugs/medicine — **72**
 - 4.4.15 Summary — **73**
 - References — **73**

Chapter 5
Hydroxytriazenes and their cobalt complexes as candidates for theoretical drug designing — 78

5.1 Introduction — **78**
5.2 Docking protocol — **80**
5.2.1 Molecular docking with human pancreatic alpha-amylase protein — **81**
5.2.2 Molecular docking with human maltase-glucoamylase protein receptor — **82**
5.2.3 Molecular docking with FAD-dependent NAD(P)H oxidase — **86**
5.3 Results of PASS prediction studies of hydroxytriazenes — **86**
5.4 ADME studies — **94**
 References — **94**

Annexure 1 — 97

Index — 113